Your browser is no longer supported. Please, upgrade your browser.
EBS Emergent BioSolutions Inc. daily Stock Chart
Emergent BioSolutions Inc.
Index- P/E56.09 EPS (ttm)1.03 Insider Own3.70% Shs Outstand51.43M Perf Week12.57%
Market Cap2.97B Forward P/E15.56 EPS next Y3.71 Insider Trans-9.91% Shs Float43.59M Perf Month-5.21%
Income54.60M PEG6.10 EPS next Q0.01 Inst Own88.80% Short Float5.18% Perf Quarter6.31%
Sales1.11B P/S2.68 EPS this Y-8.50% Inst Trans-0.04% Short Ratio4.95 Perf Half Y7.27%
Book/sh21.01 P/B2.74 EPS next Y7.54% ROA2.40% Target Price71.83 Perf Year10.21%
Cash/sh3.26 P/C17.67 EPS next 5Y9.20% ROE5.30% 52W Range39.11 - 71.19 Perf YTD6.88%
Dividend- P/FCF29.33 EPS past 5Y-2.60% ROI4.80% 52W High-19.01% Beta1.11
Dividend %- Quick Ratio2.10 Sales past 5Y22.30% Gross Margin60.80% 52W Low47.43% ATR5.50
Employees1834 Current Ratio3.20 Sales Q/Q33.10% Oper. Margin10.30% RSI (14)51.29 Volatility8.08% 11.33%
OptionableYes Debt/Eq0.75 EPS Q/Q681.50% Profit Margin4.90% Rel Volume0.78 Prev Close57.03
ShortableYes LT Debt/Eq0.73 EarningsFeb 20 AMC Payout0.00% Avg Volume456.59K Price57.66
Recom1.70 SMA203.64% SMA50-0.84% SMA2009.70% Volume357,319 Change1.10%
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-31-11Reiterated WBB Securities Strong Buy $20.50 → $30
Jan-10-11Reiterated Wedbush Outperform $27 → $32
Nov-05-10Reiterated Wedbush Outperform $22 → $27
Aug-18-10Upgrade WBB Securities Buy → Strong Buy $20.50
Aug-06-10Reiterated Caris & Company Buy $25 → $23
Jul-14-10Upgrade WBB Securities Hold → Buy $15.60 → $20.50
May-06-10Downgrade WBB Securities Buy → Hold $15.60
Apr-05-20 06:10PM  Emergent BioSolutions, Eyeing Two Plasma Therapies for Covid-19, Wins Fed's Help
Apr-03-20 02:26PM  These D.C.-area biotech companies are making progress on COVID-19. Heres the latest. American City Business Journals
12:54PM  Emergent BioSolutions gets $14.5M in federal funding to expedite COVID-19 plasma therapy development TechCrunch
07:36AM  The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO Benzinga
Apr-02-20 04:05PM  Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19 GlobeNewswire
02:51PM  Exclusive: Rockville bio raising $50M, building COVID-19 vaccine and plotting IPO American City Business Journals
Apr-01-20 09:42AM  Tiny Bay Area company aims to win coronavirus vaccine race with a tablet American City Business Journals -6.10%
06:10AM  These 19 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
Mar-31-20 05:35PM  Novavax names manufacturing partner for flu vaccine American City Business Journals +6.17%
04:05PM  Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu GlobeNewswire
Mar-29-20 07:04PM  Should You Avoid Emergent Biosolutions Inc (EBS)? Insider Monkey
Mar-25-20 06:25PM  How one company is fast-tracking development of potential plasma-based treatments for the coronavirus TechCrunch
05:00AM  Novavax could use an army to get its coronavirus vaccine to market American City Business Journals
Mar-21-20 11:30AM  Why Is Emergent Biosolutions (EBS) Down 23.6% Since Last Earnings Report? Zacks
Mar-19-20 11:55AM  Emergent (EBS) to Help Vaxart Develop Coronavirus Vaccine Zacks
Mar-18-20 12:13PM  Emergent BioSolutions dives into another coronavirus vaccine effort American City Business Journals
11:48AM  Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development Benzinga
07:54AM  Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccine MarketWatch
Mar-12-20 02:40PM  Emergent BioSolutions CEO Talks Coronavirus Vaccine Development Benzinga +6.13%
11:54AM  Emergent (EBS) Begins Development of Treatments for COVID-19 Zacks
10:30AM  Emergent BioSolutions collaborates for coronavirus vaccine Yahoo Finance Video
Mar-11-20 04:21PM  Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease GlobeNewswire -8.41%
10:27AM  Emergent BioSolutions Collaborates for Coronavirus Vaccine Zacks
Mar-10-20 11:20AM  Teladoc, Ping Identity, Emergent Biosolutions: Portfolio Manager Shares Stock Picks After Monday's Carnage Benzinga +10.24%
09:19AM  The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index Benzinga
05:30AM  Emergent BioSolutions Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease GlobeNewswire
Mar-09-20 11:27AM  A Closer Look At Emergent BioSolutions Inc.'s (NYSE:EBS) Uninspiring ROE Simply Wall St. -10.45%
07:15AM  OPNT: Pivotal PK Study for OPNT003 to Initiate in 2Q20 Zacks Small Cap Research
Mar-04-20 09:00AM  Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite GlobeNewswire +9.20%
Feb-27-20 12:32AM  Edited Transcript of EBS earnings conference call or presentation 20-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -5.31%
Feb-26-20 02:34PM  Novavax is working to advance a potential coronavirus vaccine. So are competitors. American City Business Journals
Feb-25-20 08:10AM  Coronavirus fears lead to Wall Street sell-off. Here are the D.C.-area companies hit the hardest. American City Business Journals
Feb-21-20 03:16PM  Emergent (EBS) Earnings Miss in Q4, Revenues Beat Estimates Zacks
Feb-20-20 04:31PM  Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019 GlobeNewswire
Feb-06-20 10:44AM  Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-03-20 04:30PM  Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020 GlobeNewswire
Jan-31-20 09:26AM  Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency GlobeNewswire
Jan-23-20 06:17AM  Does The Emergent BioSolutions Inc. (NYSE:EBS) Share Price Fall With The Market? Simply Wall St.
Jan-14-20 10:03AM  Emergent (EBS) Posts Preliminary '19 Results, Gives 2020 View Zacks
Jan-13-20 06:40AM  Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate GlobeNewswire
06:30AM  Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast GlobeNewswire
Jan-10-20 06:08PM  AMAG to Sell Women Healthcare Drugs, CEO Resigns, Stock Down Zacks
10:27AM  Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer Zacks
Jan-09-20 04:09PM  Catabasis (CATB) Partners with UK-Based Charity for DMD Study Zacks
10:31AM  Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib Zacks
09:48AM  Agenus Initiates Phase I Study on Oncology Candidate AGEN1223 Zacks
09:00AM  The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals Zacks
Jan-08-20 11:40AM  EBS vs. ILMN: Which Stock Is the Better Value Option? Zacks
11:26AM  Incyte's Application for Pemigatinib Gets EMA's Validation Zacks
08:30AM  5 Top Value Picks to Counter Recent Stock Market Softness Zacks
Jan-06-20 06:30AM  Emergent BioSolutions to Participate in Investor Conferences GlobeNewswire
Dec-24-19 06:15AM  Emergent BioSolutions Appears on a Healthy Trajectory
Dec-20-19 01:00PM  Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors GlobeNewswire
Dec-10-19 11:13AM  Hedge Funds Have Never Been This Bullish On Emergent Biosolutions Inc (EBS) Insider Monkey
Dec-06-19 11:31AM  Emergent Biosolutions (EBS) Down 4.4% Since Last Earnings Report: Can It Rebound? Zacks
Nov-22-19 08:19AM  Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate GlobeNewswire
Nov-21-19 04:05PM  Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day GlobeNewswire
Nov-18-19 06:30AM  Emergent BioSolutions to Host 2019 Analyst and Investor Day GlobeNewswire
Nov-13-19 02:48PM  Edited Transcript of EBS earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
09:30AM  EBS or ILMN: Which Is the Better Value Stock Right Now? Zacks
Nov-07-19 11:20AM  Emergent (EBS) Beat Earnings in Q3, Vaccines Drive Sales Zacks -5.82%
Nov-06-19 07:05PM  Emergent Biosolutions (EBS) Q3 Earnings and Revenues Beat Estimates Zacks
04:05PM  Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019 GlobeNewswire
Oct-30-19 10:34AM  Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy? Zacks
Oct-25-19 09:33AM  Can You Imagine How Chuffed Emergent BioSolutions's (NYSE:EBS) Shareholders Feel About Its 142% Share Price Gain? Simply Wall St.
Oct-21-19 11:34AM  Heres What Hedge Funds Think About Emergent Biosolutions Inc (EBS) Insider Monkey -5.17%
06:30AM  Emergent BioSolutions to Host 2019 Analyst & Investor Day GlobeNewswire
Oct-11-19 12:53PM  Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag Zacks
Oct-10-19 09:34AM  New Stocks on the Argus Focus List Yahoo Finance
06:38AM  Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate GlobeNewswire
Oct-09-19 06:30AM  Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019 GlobeNewswire
Oct-08-19 10:31AM  Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry Zacks
Sep-27-19 06:35AM  Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder GlobeNewswire
Sep-26-19 02:46PM  Emergent lands $20M contract to develop chemical weapon antidote American City Business Journals
09:27AM  Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-25-19 04:15PM  Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense GlobeNewswire
Sep-19-19 11:25AM  Emergent BioSolutions Inc. (NYSE:EBS) Insiders Have Been Selling Simply Wall St.
Sep-04-19 12:25PM  Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement Benzinga +11.69%
10:02AM  Company News For Sep 4, 2019 Zacks
Sep-03-19 01:28PM  Emergent lands federal contract for smallpox vaccine potentially worth more than $2B American City Business Journals +14.47%
12:55PM  Here's How Emergent BioSolutions Procured a Higher Price Today Motley Fool
06:30AM  Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile GlobeNewswire
Aug-31-19 09:31AM  Emergent Biosolutions (EBS) Down 0.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-28-19 02:28PM  Emergent's Vaccine Portfolio Aids Growth Amid Competition Zacks
Aug-14-19 04:15PM  Emergent BioSolutions to Participate in Series of Investor Conferences GlobeNewswire
07:48AM  Here's Why Emergent BioSolutions (NYSE:EBS) Has A Meaningful Debt Burden Simply Wall St.
Aug-06-19 10:14AM  Emergent BioSolutions Looks to the Second Half for Growth Motley Fool
06:26AM  Emergent BioSolutions Inc (EBS) Q2 2019 Earnings Call Transcript Motley Fool
Aug-05-19 01:14PM  Edited Transcript of EBS earnings conference call or presentation 1-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-02-19 10:52AM  Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates Zacks
Aug-01-19 08:25PM  Emergent Biosolutions (EBS) Q2 Earnings Lag Estimates Zacks
04:05PM  Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019 GlobeNewswire
Jul-30-19 04:42PM  Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile GlobeNewswire
Jul-25-19 10:33AM  Earnings Preview: Emergent Biosolutions (EBS) Q2 Earnings Expected to Decline Zacks
Jul-18-19 06:30AM  Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019 GlobeNewswire
Jul-09-19 06:08AM  Here's What Emergent BioSolutions Inc.'s (NYSE:EBS) P/E Is Telling Us Simply Wall St.
Jun-28-19 06:12PM  Heres What Hedge Funds Think About Emergent Biosolutions Inc (EBS) Insider Monkey
Jun-14-19 02:27PM  Before You Buy Emergent BioSolutions Inc. (NYSE:EBS), Consider Its Volatility Simply Wall St.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harsanyi ZsoltDirectorMar 16Sale65.006,400416,00029,873Mar 17 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Option Exercise13.8615,786218,71568,359Mar 06 04:37 PM
Zoon Kathryn CDirectorMar 04Sale60.6599160,10316,421Mar 06 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Sale58.9615,786930,71460,466Mar 06 04:37 PM
Bailey SueDirectorFeb 27Sale56.936,572374,13239,761Mar 02 05:28 PM
El-Hibri FuadChairmanFeb 27Sale56.979,837560,4141,469,046Feb 28 08:01 PM
El-Hibri FuadChairmanFeb 26Sale58.7013,619799,4351,472,943Feb 28 08:01 PM
El-Hibri FuadChairmanFeb 21Option Exercise25.6218,567475,6871,497,585Feb 24 08:00 PM
Richard RonaldDirectorFeb 21Option Exercise18.645,15296,03331,851Feb 25 04:30 PM
Richard RonaldDirectorFeb 21Sale65.005,152334,88016,395Feb 25 04:30 PM
Hauer Jerome MDirectorFeb 21Sale70.006,572460,04011,752Feb 25 04:28 PM
El-Hibri FuadChairmanFeb 21Sale64.9018,5671,204,9981,479,018Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 20Option Exercise25.624,751121,7211,483,769Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 20Sale64.904,751308,3401,479,018Feb 24 08:00 PM
El-Hibri FuadChairmanFeb 18Option Exercise25.6215,614400,0311,494,632Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 18Sale63.9015,614997,7351,479,018Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 14Option Exercise25.624,386112,3691,483,404Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 14Sale63.904,386280,2651,479,018Feb 19 09:00 PM
El-Hibri FuadChairmanFeb 12Option Exercise25.6213,720351,5061,492,738Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 12Sale62.9013,720862,9881,479,018Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 11Option Exercise25.626,280160,8941,485,298Feb 13 06:30 PM
El-Hibri FuadChairmanFeb 11Sale62.906,280395,0121,479,018Feb 13 06:30 PM
El-Hibri FuadExecutive ChairmanFeb 06Sale61.9011,684723,2401,419,018Feb 07 06:31 PM
El-Hibri FuadExecutive ChairmanFeb 05Sale60.6648,3162,930,8491,430,702Feb 07 06:31 PM
Harsanyi ZsoltDirectorJan 16Sale55.003,435188,92536,273Jan 17 04:19 PM
Bailey SueDirectorDec 12Sale53.468,375447,72846,333Dec 13 09:21 AM
Zoon Kathryn CDirectorNov 18Sale54.311,00054,31417,412Nov 19 04:11 PM
Zoon Kathryn CDirectorNov 08Sale54.153,082166,88418,412Nov 12 09:52 AM
Richard RonaldDirectorNov 07Option Exercise18.645,15396,05231,852Nov 12 09:51 AM
Richard RonaldDirectorNov 07Sale60.005,153309,18026,699Nov 12 09:51 AM
Zoon Kathryn CDirectorSep 09Sale56.121,50984,69221,494Sep 10 05:44 PM
Zoon Kathryn CDirectorMay 28Sale43.391,37659,70223,003May 28 08:18 PM
SULLIVAN LOUIS WDirectorMay 07Option Exercise13.377,893105,52956,865May 09 05:18 PM